Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Students, Pharmacy | 10 | 2024 | 73 | 3.980 |
Why?
|
| Education, Pharmacy | 9 | 2024 | 73 | 3.510 |
Why?
|
| Nonprescription Drugs | 7 | 2018 | 7 | 2.260 |
Why?
|
| Humans | 45 | 2024 | 4936 | 2.100 |
Why?
|
| Female | 33 | 2024 | 2523 | 1.950 |
Why?
|
| Adult | 28 | 2024 | 1567 | 1.890 |
Why?
|
| United States | 17 | 2024 | 495 | 1.860 |
Why?
|
| Prescription Drugs | 4 | 2023 | 15 | 1.820 |
Why?
|
| Male | 31 | 2024 | 2491 | 1.730 |
Why?
|
| Retrospective Studies | 13 | 2024 | 341 | 1.700 |
Why?
|
| Health Expenditures | 5 | 2024 | 18 | 1.630 |
Why?
|
| Cross-Sectional Studies | 18 | 2024 | 269 | 1.470 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 39 | 1.430 |
Why?
|
| Aged | 15 | 2024 | 703 | 1.360 |
Why?
|
| Drug Labeling | 4 | 2018 | 4 | 1.330 |
Why?
|
| Students | 4 | 2021 | 120 | 1.290 |
Why?
|
| Surveys and Questionnaires | 13 | 2024 | 258 | 1.280 |
Why?
|
| Middle Aged | 18 | 2024 | 967 | 1.270 |
Why?
|
| Curriculum | 3 | 2024 | 48 | 1.220 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2020 | 10 | 1.210 |
Why?
|
| Medication Adherence | 3 | 2023 | 69 | 1.080 |
Why?
|
| Quality of Life | 3 | 2015 | 87 | 1.060 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 17 | 0.970 |
Why?
|
| Medicare Part C | 2 | 2016 | 32 | 0.950 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2016 | 7 | 0.950 |
Why?
|
| Attitude of Health Personnel | 4 | 2016 | 20 | 0.930 |
Why?
|
| School Admission Criteria | 3 | 2023 | 10 | 0.930 |
Why?
|
| Health Status Disparities | 1 | 2024 | 10 | 0.870 |
Why?
|
| Life Change Events | 2 | 2023 | 16 | 0.840 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 9 | 0.840 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 43 | 0.840 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2022 | 20 | 0.840 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2024 | 16 | 0.840 |
Why?
|
| Immunotherapy | 1 | 2024 | 20 | 0.840 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 25 | 0.820 |
Why?
|
| Texas | 9 | 2024 | 190 | 0.780 |
Why?
|
| Medicare Part D | 2 | 2020 | 7 | 0.760 |
Why?
|
| Educational Measurement | 5 | 2024 | 49 | 0.760 |
Why?
|
| Health Status | 3 | 2024 | 27 | 0.750 |
Why?
|
| Diabetes Complications | 1 | 2022 | 5 | 0.740 |
Why?
|
| Complementary Therapies | 2 | 2013 | 2 | 0.740 |
Why?
|
| Cognition | 3 | 2018 | 140 | 0.700 |
Why?
|
| Health Status Indicators | 2 | 2014 | 8 | 0.700 |
Why?
|
| Schools, Pharmacy | 4 | 2024 | 24 | 0.680 |
Why?
|
| Young Adult | 9 | 2024 | 787 | 0.660 |
Why?
|
| Mental Disorders | 1 | 2021 | 48 | 0.650 |
Why?
|
| Pharmacy | 1 | 2020 | 16 | 0.630 |
Why?
|
| Medication Therapy Management | 2 | 2016 | 6 | 0.630 |
Why?
|
| Universities | 3 | 2018 | 80 | 0.600 |
Why?
|
| Patient Education as Topic | 2 | 2017 | 7 | 0.600 |
Why?
|
| Early Detection of Cancer | 2 | 2016 | 7 | 0.590 |
Why?
|
| Perception | 3 | 2016 | 32 | 0.570 |
Why?
|
| Health Services | 1 | 2018 | 8 | 0.570 |
Why?
|
| Interviews as Topic | 1 | 2018 | 24 | 0.570 |
Why?
|
| Intention | 3 | 2016 | 19 | 0.560 |
Why?
|
| Hospitalization | 1 | 2018 | 38 | 0.560 |
Why?
|
| Psychological Theory | 3 | 2016 | 22 | 0.560 |
Why?
|
| Pamphlets | 1 | 2017 | 1 | 0.530 |
Why?
|
| Adolescent | 8 | 2018 | 758 | 0.520 |
Why?
|
| Disabled Children | 1 | 2017 | 1 | 0.520 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2017 | 1 | 0.520 |
Why?
|
| Reading | 1 | 2018 | 74 | 0.510 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 14 | 0.500 |
Why?
|
| Communication | 1 | 2016 | 28 | 0.500 |
Why?
|
| Parenting | 1 | 2017 | 48 | 0.490 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 32 | 0.490 |
Why?
|
| Chronic Disease | 1 | 2016 | 25 | 0.480 |
Why?
|
| Patient Compliance | 1 | 2015 | 17 | 0.460 |
Why?
|
| Stress, Psychological | 1 | 2017 | 86 | 0.460 |
Why?
|
| Social Class | 1 | 2015 | 20 | 0.450 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 26 | 0.450 |
Why?
|
| Prescription Drug Overuse | 1 | 2015 | 1 | 0.450 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 96 | 0.410 |
Why?
|
| Formularies as Topic | 2 | 2004 | 2 | 0.400 |
Why?
|
| Public Opinion | 1 | 2013 | 2 | 0.400 |
Why?
|
| Attitude to Health | 1 | 2013 | 13 | 0.390 |
Why?
|
| Pharmacists | 4 | 2009 | 41 | 0.390 |
Why?
|
| Emigrants and Immigrants | 1 | 2013 | 26 | 0.380 |
Why?
|
| Achievement | 2 | 2015 | 16 | 0.370 |
Why?
|
| Cost of Illness | 1 | 2011 | 4 | 0.360 |
Why?
|
| Cystic Fibrosis | 1 | 2011 | 6 | 0.360 |
Why?
|
| Pseudomonas Infections | 1 | 2011 | 18 | 0.350 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2011 | 34 | 0.350 |
Why?
|
| Cohort Studies | 2 | 2024 | 115 | 0.350 |
Why?
|
| Physicians | 3 | 2016 | 17 | 0.340 |
Why?
|
| Education, Pharmacy, Graduate | 2 | 2024 | 5 | 0.340 |
Why?
|
| Health Surveys | 2 | 2008 | 13 | 0.340 |
Why?
|
| Pharmaceutical Services | 2 | 2016 | 18 | 0.310 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 262 | 0.310 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 47 | 0.290 |
Why?
|
| Medicare | 2 | 2020 | 78 | 0.290 |
Why?
|
| United States Food and Drug Administration | 2 | 2024 | 5 | 0.280 |
Why?
|
| Ephedrine | 1 | 2008 | 1 | 0.280 |
Why?
|
| Pseudoephedrine | 1 | 2008 | 1 | 0.280 |
Why?
|
| Heart Diseases | 1 | 2008 | 11 | 0.270 |
Why?
|
| Language | 1 | 2007 | 51 | 0.260 |
Why?
|
| Motivation | 1 | 2006 | 69 | 0.240 |
Why?
|
| Risk Factors | 2 | 2016 | 159 | 0.230 |
Why?
|
| Drug Packaging | 1 | 2005 | 1 | 0.220 |
Why?
|
| Psychometrics | 2 | 2017 | 94 | 0.220 |
Why?
|
| Marijuana Abuse | 1 | 2024 | 9 | 0.220 |
Why?
|
| Genetic Testing | 1 | 2004 | 2 | 0.210 |
Why?
|
| Drug Approval | 1 | 2024 | 1 | 0.210 |
Why?
|
| Cross-Over Studies | 1 | 2024 | 31 | 0.210 |
Why?
|
| Consumer Behavior | 1 | 2004 | 2 | 0.210 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2004 | 2 | 0.210 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 318 | 0.210 |
Why?
|
| Child, Preschool | 2 | 2017 | 180 | 0.200 |
Why?
|
| Anxiety | 2 | 2021 | 167 | 0.200 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2023 | 3 | 0.200 |
Why?
|
| Demography | 1 | 2023 | 16 | 0.200 |
Why?
|
| Comprehension | 2 | 2017 | 31 | 0.200 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 38 | 0.190 |
Why?
|
| Neoplasms | 1 | 2023 | 90 | 0.180 |
Why?
|
| Academic Success | 1 | 2021 | 8 | 0.180 |
Why?
|
| Child | 2 | 2017 | 627 | 0.170 |
Why?
|
| College Admission Test | 1 | 2020 | 3 | 0.160 |
Why?
|
| Insurance Coverage | 1 | 2020 | 3 | 0.160 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 15 | 0.150 |
Why?
|
| HIV Infections | 2 | 2014 | 104 | 0.150 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 28 | 0.140 |
Why?
|
| Logistic Models | 1 | 2018 | 64 | 0.140 |
Why?
|
| Patient Participation | 1 | 2017 | 4 | 0.130 |
Why?
|
| Internship and Residency | 1 | 2016 | 6 | 0.130 |
Why?
|
| Forecasting | 1 | 2016 | 19 | 0.130 |
Why?
|
| Hydrocodone | 1 | 2016 | 3 | 0.120 |
Why?
|
| Controlled Substances | 1 | 2016 | 4 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2016 | 44 | 0.120 |
Why?
|
| Parent-Child Relations | 1 | 2017 | 43 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2016 | 1 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2016 | 2 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2011 | 111 | 0.120 |
Why?
|
| Liver Cirrhosis | 1 | 2016 | 7 | 0.120 |
Why?
|
| Community Pharmacy Services | 2 | 2008 | 8 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 9 | 0.120 |
Why?
|
| Data Collection | 2 | 2007 | 14 | 0.120 |
Why?
|
| Arabs | 1 | 2015 | 2 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 16 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 47 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2016 | 26 | 0.120 |
Why?
|
| Health Behavior | 1 | 2015 | 34 | 0.120 |
Why?
|
| Mammography | 1 | 2015 | 7 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 73 | 0.110 |
Why?
|
| Tobacco Products | 1 | 2015 | 36 | 0.110 |
Why?
|
| Age Factors | 1 | 2015 | 65 | 0.110 |
Why?
|
| Self Report | 1 | 2015 | 67 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2015 | 75 | 0.110 |
Why?
|
| Smoking Cessation | 1 | 2015 | 135 | 0.100 |
Why?
|
| Phytotherapy | 1 | 2013 | 5 | 0.100 |
Why?
|
| Patient Satisfaction | 1 | 2013 | 24 | 0.100 |
Why?
|
| Time Management | 2 | 2015 | 2 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2011 | 70 | 0.090 |
Why?
|
| Medication Systems, Hospital | 1 | 2011 | 1 | 0.090 |
Why?
|
| Medication Errors | 1 | 2011 | 4 | 0.090 |
Why?
|
| Nurses | 1 | 2011 | 2 | 0.090 |
Why?
|
| Infant | 1 | 2011 | 78 | 0.090 |
Why?
|
| Educational Status | 2 | 2015 | 29 | 0.080 |
Why?
|
| Computers, Handheld | 1 | 2009 | 6 | 0.080 |
Why?
|
| Self Medication | 1 | 2008 | 2 | 0.070 |
Why?
|
| Commerce | 1 | 2008 | 1 | 0.070 |
Why?
|
| Legislation, Drug | 1 | 2008 | 1 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 8 | 0.070 |
Why?
|
| Substance-Related Disorders | 1 | 2008 | 47 | 0.070 |
Why?
|
| Test Anxiety Scale | 1 | 2006 | 1 | 0.060 |
Why?
|
| Social Behavior | 1 | 2006 | 22 | 0.060 |
Why?
|
| Personal Satisfaction | 1 | 2006 | 24 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2006 | 137 | 0.060 |
Why?
|
| Bioethics | 1 | 2004 | 1 | 0.050 |
Why?
|
| Human Genome Project | 1 | 2004 | 4 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2004 | 5 | 0.050 |
Why?
|
| Health Services Research | 1 | 2004 | 3 | 0.050 |
Why?
|
| Managed Care Programs | 1 | 2004 | 7 | 0.050 |
Why?
|
| Attitude | 1 | 2004 | 14 | 0.050 |
Why?
|
| Emergency Service, Hospital | 1 | 2023 | 12 | 0.050 |
Why?
|
| Drug Information Services | 1 | 2003 | 1 | 0.050 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2003 | 5 | 0.050 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2003 | 4 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2003 | 14 | 0.050 |
Why?
|
| Teaching | 1 | 2021 | 11 | 0.040 |
Why?
|
| Faculty | 1 | 2021 | 15 | 0.040 |
Why?
|
| Drug and Narcotic Control | 1 | 2016 | 3 | 0.030 |
Why?
|
| United States Government Agencies | 1 | 2016 | 3 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2016 | 31 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 2016 | 1 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2016 | 4 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2016 | 3 | 0.030 |
Why?
|
| Office Visits | 1 | 2016 | 3 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 19 | 0.030 |
Why?
|
| Performance Anxiety | 1 | 2015 | 2 | 0.030 |
Why?
|
| Nigeria | 1 | 2015 | 7 | 0.030 |
Why?
|
| Time and Motion Studies | 1 | 2011 | 1 | 0.020 |
Why?
|
| Workflow | 1 | 2011 | 2 | 0.020 |
Why?
|
| Patient Care | 1 | 2011 | 4 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2011 | 17 | 0.020 |
Why?
|
| Critical Care | 1 | 2011 | 12 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 30 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 6 | 0.020 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2008 | 6 | 0.020 |
Why?
|